The Efficacy of Mirodenafil for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Middle-Aged Males.
10.5534/wjmh.2014.32.3.145
- Author:
Do Hoon KONG
1
;
Chang Jin YUN
;
Hyun Jun PARK
;
Nam Cheol PARK
Author Information
1. Department of Urology, Pusan National University School of Medicine, Busan, Korea. joon501@naver.com
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Chronic prostatitis with chronic pelvic pain syndrome;
Erectile dysfunction;
Phosphodiesterase 5 inhibitors;
Treatment outcome
- MeSH:
Erectile Dysfunction;
Humans;
Levofloxacin;
Male;
National Institutes of Health (U.S.);
Pelvic Pain*;
Phosphodiesterase 5 Inhibitors;
Prostate;
Prostatitis;
Quality of Life;
Surveys and Questionnaires;
Treatment Outcome
- From:The World Journal of Men's Health
2014;32(3):145-150
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to investigate the efficacy of mirodenafil in middle-aged male patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). MATERIALS AND METHODS: Eighty-eight males with CP/CPPS were randomized to receive either levofloxacin (500 mg/d) (group L, 40 patients) or levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML, 48 patients) for six weeks. The International Prostate Symptom Score (IPSS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire were used to grade symptoms at baseline and 6 weeks after treatment. RESULTS: The mean change in total IPSS from baseline was higher in group ML than that in group L (group L, -1.1 vs. group ML, -4.3; p<0.05). Significant improvements were also seen in the IPSS voiding subscore (group L, -0.7 vs. group ML, -3.0; p<0.05). Changes observed in the NIH-CPSI of group ML at six weeks were greater than those at baseline (group L, -3.2 vs. group ML, -7.2; p<0.05). Significant improvements were seen in the NIH-CPSI voiding (group L, -0.5 vs. group ML, -1.7; p<0.05) and quality of life domains (group L, -1.0 vs. group ML, -1.8; p<0.05). Group ML showed a significantly greater increase in the IIEF-EF score than did group ML (group L, +0.2 vs. group ML, +7.8; p<0.05). CONCLUSIONS: Mirodenafil (50 mg once daily) was well tolerated and resulted in significant symptomatic improvement in middle-aged males with CP/CPPS.
